“Tirzepatide (Mounjaro/Zepbound) is FDA-approved to treat fatty liver disease (MASH).”
What the evidence shows
In August 2025 the FDA approved semaglutide (Wegovy) for noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis, based on the phase-3 ESSENCE trial, in which about 63% of people had MASH resolution without worsening fibrosis versus placebo. That fatty-liver approval is for semaglutide only.
What we still don’t know
Tirzepatide has shown promise for MASH in an earlier phase-2 trial (SYNERGY-NASH), but its confirmatory phase-3 liver-outcomes trial is still running, and long-term liver-outcome data for both drugs are years away. Whether tirzepatide will earn a MASH approval — and how the two compare head-to-head for the liver — is not yet known.
Why the claim misleads
The claim is commonly repeated on peptide-seller and telehealth sites, but it conflates a phase-2 signal with an FDA approval. As of mid-2026, tirzepatide is NOT FDA-approved for MASH; semaglutide is. Treating an investigational use as an approved one is exactly the kind of overstatement that leads people to expect coverage and outcomes that don't yet exist.
Graded by The Peptide Era · evidence, not hype